Back

Variability in echocardiographic surveillance for cardiotoxicity in HER2+ versus HER2- breast cancer: a SEER-medicare analysis

30 August 2025 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology and therapy Diagnosis and Management of Cardiovascular Disease in Patients with Cancer ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Associate Professor Jordan Strom

Beth Israel Deaconess Medical Center, Boston (United States of America)

3 More presentations in this session

Presentation thumbnail
NLRP3/IL-1 pathway was reduced by semaglutide and dapagliflozin in association therapy under exposure to anthracyclines in hyperglycemic conditions
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Age- and sex-specific association between clonal hematopoiesis of indeterminate potential and pulmonary hypertension
Doctor G. Sun (Guangzhou, CN)
Abstract Slides Video
Presentation thumbnail
The role of TAK1 inhibition in doxorubicin-induced cardiotoxicity: an in vitro study
Associate Professor B. Polegato (Botucatu, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology and therapy

The Event

Event poster

ESC Congress 2025

30 August 2025 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Speckle-tracking echocardiography in chemotherapy-induced cardiotoxicity: a predictor or monitoring tool?
thumbnail
Congress Presentation
Evaluation of the predictive value of the HFA-ICOS score for cardiotoxicity in breast cancer patients treated with anthracyclines and trastuzumab: a real-world observational study
thumbnail
Congress Presentation
New onset of left ventricular dysfunction and diastolic dysfunction are uncommon in patients with her2+ breast cancer after completion of cancer therapy.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources